U.S. markets closed

  • S&P Futures

    3,930.50
    +2.50 (+0.06%)
     

  • Dow Futures

    31,592.00
    +43.00 (+0.14%)
     

  • Nasdaq Futures

    13,684.00
    -15.75 (-0.11%)
     

  • Russell 2000 Futures

    2,259.10
    +4.10 (+0.18%)
     

  • Crude Oil

    61.86
    +0.72 (+1.18%)
     

  • Gold

    1,783.90
    +11.10 (+0.63%)
     

  • Silver

    27.58
    +0.26 (+0.97%)
     

  • EUR/USD

    1.2042
    -0.0004 (-0.04%)
     

  • 10-Yr Bond

    1.3010
    +0.0020 (+0.15%)
     

  • Vix

    21.50
    +0.04 (+0.19%)
     

  • GBP/USD

    1.3852
    -0.0012 (-0.08%)
     

  • USD/JPY

    105.8690
    -0.0020 (-0.00%)
     

  • BTC-USD

    52,238.93
    +2,167.07 (+4.33%)
     

  • CMC Crypto 200

    1,060.49
    +68.48 (+6.90%)
     

  • FTSE 100

    6,710.90
    -37.96 (-0.56%)
     

  • Nikkei 225

    30,344.97
    +52.78 (+0.17%)
     

CLASS ACTION UPDATE for TRIT, TCDA and AZN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE /February 17, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff ... Levi & Korsinsky, LLP

NEW YORK, NY / ACCESSWIRE / February 17, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

TRIT Shareholders Click Here: https://www.zlk.com/pslra-1/triterras-inc-f-k-a-netfin-acquisition-corp-loss-submission-form?prid=12967&wire=1
TCDA Shareholders Click Here: https://www.zlk.com/pslra-1/tricida-inc-loss-submission-form?prid=12967&wire=1
AZN Shareholders Click Here: https://www.zlk.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=12967&wire=1

* ADDITIONAL INFORMATION BELOW *

Triterras, Inc., f/k/a Netfin Acquisition Corp. (NASDAQ:TRIT)

TRIT Lawsuit on behalf of: investors who purchased August 20, 2020 - December 16, 2020
Lead Plaintiff Deadline : February 19, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/triterras-inc-f-k-a-netfin-acquisition-corp-loss-submission-form?prid=12967&wire=1

According to the filed complaint, during the class period, Triterras, Inc., f/k/a Netfin Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) the extent to which Company's revenue growth relied on Triterras' relationship with Rhodium to refer users to the Kratos platform; (2) that Rhodium faced significant financial liabilities that jeopardized its ability to continue as a going concern; (3) that, as a result, Rhodium was likely to refer fewer users to the Company's Kratos platform; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Tricida, Inc. (NASDAQ:TCDA)

TCDA Lawsuit on behalf of: investors who purchased September 4, 2019 - October 28, 2020
Lead Plaintiff Deadline : March 8, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tricida-inc-loss-submission-form?prid=12967&wire=1

According to the filed complaint, during the class period, Tricida, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Tricida's NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Astrazeneca Plc (NYSE:AZN)

AZN Lawsuit on behalf of: investors who purchased May 21, 2020 - November 20, 2020
Lead Plaintiff Deadline : March 29, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=12967&wire=1

According to the filed complaint, during the class period, Astrazeneca Plc made materially false and/or misleading statements and/or failed to disclose that: (a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca's clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/630452/CLASS-ACTION-UPDATE-for-TRIT-TCDA-and-AZN-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Latest Stories

  • Marijuana Stock Tilray Surges on Upbeat Q4 Report, Aphria Deal Outlook

    Tilray's fourth-quarter loss was narrower than expected, while sales were slightly higher than estimates. CEO Brendan Kennedy sounded positive notes for the merger with Aphria.

  • Warren Buffett's Berkshire Cuts Apple Stake And Buys These Drugmaker, Telecom Stocks Instead

    Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) cut its positions in Apple Inc (NASDAQ: AAPL) and piled on stocks of drug, telecom, and oil companies in the latest quarter, according to filings made with the U.S. Securities and Exchange Commission. What Happened: The Warren Buffett-led company shed its Apple stake by 6% to 887 million shares in the quarter, but at the same time has upped its investments in AbbVie Inc (NYSE: ABBV) by 20%, Bristol-Myers Squibb Company (NYSE: BMY) by 11%, and Merck & Co, Inc (NYSE: MRK) by 28%. The conglomerate increased its exposure to T-Mobile US, Inc (NASDAQ: TMUS) by 1.36% to 5.2 million shares and also added 146.7 million shares of Verizon Communications Inc (NYSE: VZ). See Also: Warren Buffett's Berkshire Bets On These Four Drugmakers Amid Pandemic Berkshire picked up a fresh stake of 48.5 million Chevron Corporation (NYSE: CVX) shares and increased its investment in The Kroger Co (NYSE: KR) by 34%. Other changes include a 59% cut in exposure to Wells Fargo & Co (NYSE: WFC) and a 28% cut in Suncor Energy Inc (NYSE: SU) stake. Why It Matters: Apple is still the largest single investment in Berkshire’s portfolio, as of the latest 13F filing, and the investment is worth about $120 billion. See Also: Warren Buffett Called Bitcoin 'Rat Poison' — Now It's Closing In On Berkshire Hathaway's Valuation Apple shares closed nearly 1.6% lower at $133.19 on Tuesday and fell another 0.41% in the after-hours session. In the after-hours trading on Tuesday — AbbVie shares were up 0.42% at $104.64. Bristol-Myers shares rose 0.34% to $59.60. T-Mobile shares rose 0.86% to $123.05. Verizon shares shot up 3.05% to $55.80 in the after-hours trading, while Chevron shares rose 2.54% to $95.50. Wells Fargo shares were down 0.11% in the after-hours. Kroger and Suncor shares remained largely unchanged. Price Action: Berkshire Hathaway Class A shares closed 1.23% higher at $369,333. The company’s class B shares closed 1.15% higher at $245.28 and fell 0.11% in the after-hours session. Photo by Fortune Live Media on Flickr See more from BenzingaClick here for options trades from BenzingaTikTok In Negotiations To Go Public On NYSE: Chinese MediaWhy Apple Getting Increasingly Serious About Making Cars? 'Transportation' Dwarfs 'Smartphone' Market, Says Munster© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Stocks To Watch: Square Among 7 Stocks Expecting Up To 128% Growth In 2021

    What are the fastest-growing stocks to watch in 2021? Here's a list featuring DocuSign, Square, Daqo and four other stocks expecting up to 128% growth.

  • Cathie Wood Talks Tesla, Bitcoin, SPACs And More On CNBC: Here Are The Highlights

    Famed investor and ETF manager Cathie Wood joined Scott Wapner and Bob Pisani on the “Halftime Report” on CNBC Wednesday to share opinions on some holdings across her funds. Wood On Tesla: Wood has been a notable bull on Tesla Inc (NASDAQ: TSLA) and it remains the largest holding in the signature Ark Innovation ETF (NYSE: ARKK). “Our confidence in Tesla has grown,” Wood said. The fund manager said no one is modeling the ride-share potential for Tesla when forecasting revenue and price targets. Rideshare could be more profitable for Tesla than electric vehicles. Related Link: 7 Stocks That Fit Cathie Wood’s Big Ideas 2021, Could Be Added To Ark ETFs Wood On Bitcoin: Wood has been bullish on Bitcoin recently hitting on the rise in valuation that could be seen if every S&P 500 company allocated 1% of cash to the cryptocurrency. “We have individuals now who really understand,” Wood said on Gary Gensler, the new U.S. SEC Chair. Gensler taught a class on blockchain and Bitcoin at MIT and understand the technology and valuation, Wood added. The Grayscale Bitcoin Trust (OTC: GBTC) is a popular option for investors in the U.S. to get exposure to Bitcoin as no ETFs are available currently. Wood said the probability of a Bitcoin ETF goes up with new administration understanding cryptocurrency. The fund manager praises companies like Tesla and Square Inc (NYSE: SQ) who are “on the right side of change” by adding Bitcoin and diversifying their cash holdings. Wood On Telemedicine: One of the largest holdings in the Ark ETFs is Teladoc Health (NYSE: TDOC). The telemedicine company is held in the Ark Innovation ETF, Ark Genomic Internet ETF (BATS: ARKG) and Ark Next Generation Internet ETF (NYSE: ARKW). “We had a great opportunity to buy into Teladoc when stay-at-home stocks flattened out,” Wood said. Despite the stock being up 40% in 2021, Wood remains bullish and thinks the company was hurt by public sentiment of the acquisition of Livongo. “This is a beautiful acquisition for Teladoc,"Wood said, adding that the two companies will create a powerhouse of data together. Wood on SPACs: The Ark fund manager has added several SPACs to the portfolio recently, including some that have completed mergers and others like Experience Investment (NASDAQ: EXPC) that are in the merger process. Wood named DraftKings Inc (NASDAQ: DKNG), Skillz (NYSE: SKLZ) and Butterfly Network Inc (NYSE: BFLY) as former SPACs that the Ark funds own. “We are investing in them,” Wood said of SPACs. “We’re being very careful.” Wood said the fund is selective and doesn’t like the incentive structure of some SPACs. The fund manager noted SPACs remain a way for the public markets to invest in some growth sooner than the traditional IPO route. Space ETF: Wood is launching a space ETF under the Ark umbrella of funds soon. Due to a quiet period with the SEC, Wood couldn’t discuss specific space stocks, but was bullish on the overall industry. She called space exploration the right side of change. “We see SpaceX, Blue Origin pushing the envelope,” Wood said of the private companies. She highlighted the work that Elon Musk, Jeff Bezos and Richard Branson have done in the space industry. The costs of launching rockets are coming down dramatically, which could lead to strong growth in the sector, according to Wood. See more from BenzingaClick here for options trades from BenzingaQuantumScape Could Have Breakthrough EV Battery Technology: WedbushOrigin Materials Lands SPAC Deal: What Investors Should Know About Pepsi-, Danone-, Nestle-Backed Company© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Warren Buffett is right to bet big on 5G: former Cisco CEO

    Former Cisco CEO John Chambers weighs in on Warren Buffett's big bets on 5G.

  • Warren Buffett's favorite indicator is at a dangerous level, but he just bought these stocks anyway

    Warren Buffett goes on the hunt for stocks in the fourth quarter, according to a new filing.

  • Palantir Stock Falls As 2021 Revenue Outlook Disappoints, IPO Lock-Up To Expire

    Palantir stock fell as full-year 2021 revenue guidance came in slightly below expectations. Palantir stock also faces a test on Thursday when its IPO lock-up period expires.

  • ‘Roaring Kitty’ Sued for Securities Fraud Over GameStop Rise

    (Bloomberg) -- Keith Gill, one of the most influential voices that pushed GameStop on the WallStreetBets Reddit forum, was hit with a lawsuit that accused him of misrepresenting himself as an amateur investor and profiting by artificially inflating the price of the stock.The proposed class action against Gill, who adopted the YouTube nickname “Roaring Kitty,” was filed Tuesday in federal court in Massachusetts. The suit said Gill was actually a licensed securities professional who manipulated the market to profit himself. Gill touted GameStop shares through an extensive social media presence on Youtube, Twitter and Reddit, where he used a more profane alias.“Gill’s deceitful and manipulative conduct not only violated numerous industry regulations and rules, but also various securities laws by undermining the integrity of the market for GameStop shares,” the suit said. “He caused enormous losses not only to those who bought option contracts, but also to those who fell for Gill’s act and bought GameStop stock during the market frenzy at greatly inflated prices.”The suit was filed by the securities class action firm Hagens Berman Sobol Shapiro on behalf of Christian Iovin of Washington state and similarly situated individuals. Iovin sold $200,000 worth of call options on GameStop shares when the stock was below $100. The stock quickly eclipsed $400 a share, forcing him to buy the calls back at elevated prices.Gill became one of the public faces of the GameStop rally that has been a Wall Street obsession this year. The stock’s stratospheric rise appeared to pit scrappy individual investors against sophisticated hedge funds who were heavily shorting the troubled mall retailer. Some funds lost billions of dollars covering their positions as GameStop shares surged more than 1,700% during one stretch in January.Congressional TestimonyThe GameStop rally has also attracted the attention of politicians, and Gill is scheduled to testify Thursday before the House Financial Services Committee, along with executives from Robinhood Markets, Citadel LLC, Melvin Capital Management and Reddit.In prepared testimony for his Congressional appearance, provided in advance by his lawyer in response to questions about the lawsuit, Gill said his previous work in the financial industry never included trading securities or advising clients. He also denied trying to artificially pump up GameStop shares and said he truly believed in the company’s future potential.“I did not solicit anyone to buy or sell the stock for my own profit,” Gill plans to testify. “I did not belong to any groups trying to create movements in the stock price. I never had a financial relationship with any hedge fund. I had no information about GameStop except what was public. I did not know any people inside the company, and I never spoke to any insider.”‘Millionaires’ in DecemberIt’s unclear how much money Gill made from his GameStop shares, though he said in his testimony that he and his family were “millionaires” when the stock reached $20 in December, far below the heights it would reach a month later. Those gains have largely evaporated in recent weeks, with the stock trading around $47 on Wednesday afternoon.The lawsuit claims Gill, who has been written about extensively by Bloomberg, The New York Times, The Wall Street Journal and others, was far from being an amateur stock picker. Rather, he is a Chartered Financial Analyst who holds multiple broker licenses and was previously employed by Massachusetts Mutual Life Insurance Co. The lawsuit also named Mass Mutual and a brokerage subsidiary of the company as defendants, saying they had an obligation to supervise Gill’s activities in the market.A spokeswoman for Mass Mutual said the company was reviewing the matter and had no comment.“In order to motivate amateur traders, Gill fashioned himself as a kind of Robin Hood and characterized securities professionals as villians,” the lawsuit said. “Gill, however, is no amateur. For many years, he actively worked as a professional in the investment and financial industries.”The case is Iovin v. Gill, 21-cv-10264, U.S. District Court District, District of Massachusetts (Springfield).(Updates with Gill’s planned testimony to Congress)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Should AT&T Or Verizon Try To Acquire Nokia In 2021?

    Every week, Benzinga conducts a survey to collect sentiment on what traders are most excited about, interested in or thinking about as they manage and build their personal portfolios. This week we posed the following question to over 1,000 traders and investors as to if 5G wireless giants AT&T Inc. (NYSE: T) or Verizon Communications Inc. (NYSE: VZ) should acquire Nokia (NYSE: NOK) in 2021: AT&T should buy Nokia Verizon should buy Nokia Neither should buy Nokia Given AT&T and Verizon are the nation’s largest wireless carriers, it’s expected they will be the most competitive companies angling for the largest market share of 5G cellular technology in the coming years. Verizon is the largest U.S. wireless carrier, serving about 89 million postpaid and 4 million prepaid phone customers. AT&T is the second-largest U.S. wireless carrier, with 63 million postpaid and 16 million prepaid phone customers. Verizon + Nokia: As far as active business relationships are concerned, in October Verizon teamed up with Nokia to offer private 5G capabilities to enterprises across Europe and Asia-Pacific territories. Private 5G will enable organizations to deliver mission-critical and real-time capabilities and Verizon's continued investment in 5G and network-as-a-service strategy, the companies said. See Also: How To Buy Verizon Stock AT&T + Nokia: As is the case with Verizon, it’s no secret AT&T and Nokia have an active partnership in place to leverage their 5G technologies. The agreement between AT&T and Nokia highlights how AT&T’s enterprise customers can connect and manage a multitude of Internet of Things (IoT) devices on their networks, leveraging Nokia WING’s capabilities, including increased performance and flexibility, and lower latency. The current AT&T-Nokia partnership also underscores how, as IoT networks transition to 5G and with Nokia WING also supporting 5G network slicing, AT&T will be able to partition its 5G network into multiple networks that can deliver specific capabilities to its IoT customers and support various use cases. Survey Says: While the 5G partnership caught the eye of our respondents, only 28% felt Verizon should move forward with completing an M&A with Nokia by the end of the year. About 30% of respondents believe an AT&T-Nokia makes sense in 2021. Meanwhile, 42% of respondents told us both AT&T and Verizon ought not attempt an M&A deal in 2021. Many respondents simply believe Nokia has the possibility to revamp itself, or that Nokia simply carries too much debt for AT&T and Verizon to bother taking on. Nokia's long-term debt stands at $5.1 billion at the time of publication. See more from BenzingaClick here for options trades from BenzingaHere's Why MicroVision, Verizon And Slack Are MovingWe Asked 1,000 Readers If Tesla Or Nio Makes The Cooler-Looking EV© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Warren Buffett Dumped GOLD Stock Ahead Of Gold-Price Death Cross

    Massive new fiscal spending under Democrats supports the gold bull case long term, but faster Fed tightening could weigh on gold for a while.

  • We were ‘dangerously close’ to collapse of ‘entire system,’ says Interactive Brokers founder ahead of GameStop hearing

    Thomas Peterffy, founder and chairman of Interactive Brokers Group Inc., on Wednesday explained the dire situation in which the market stood in late January as individual investors on social-media platforms were banding together to send a handful of heavily shorted stocks dramatically higher.

  • When to expect your next stimulus check? These dates are key to the timing

    Congress is burning rubber to get a bill to President Biden in a race against time.

  • The Bottom Is in for These 2 Stocks? Analysts Say ‘Buy’

    Today, we’re looking at two small-cap biotech firms whose stocks have struck a rut. Each company has hit a recent clinical setback that sent the share price falling, erasing previous gains and sending it back down to low levels. Setbacks of this sort are not uncommon in the biotech industry, and in fact highlight the risk and speculative nature of the industry. So what should investors do, when a stock collapses? Is this a matter of poor fundamentals? And has the stock’s price found its low point yet? That’s where the Wall Street pros come in. Noting that each is set to take back off on an upward trajectory, some 5-star analysts see an attractive entry point for both. Using TipRanks’ database, we found out that these two tickers have earned Moderate or Strong Buy consensus ratings from the analyst community, and boast strong upside potential. Cortexyme, Inc. (CRTX) The first beaten-down name we're looking at is Cortexyme, a clinical-stage biopharma company focused on degenerative diseases, especially Alzheimer’s. The company's lead candidate is COR388, also called atuzaginstat. Atuzaginstat is currently under investigation in the GAIN trial, a study of its efficacy against Alzheimer’s disease. The trial is fully enrolled, with 643 patients, and the company was moving toward an open label enrollment (OLE) section of the Phase 2/3 study. During a routine regulatory update, Cortexyme announced that the OLE phase would be halted, although the primary GAIN study will continue, with results due to be released in Q4 2021. The announcement of the partial halt triggered a 35% drop in share price. The partial hold was prompted by adverse events on the liver during the atuzaginstat trial. The hepatic symptoms were reversible and showed no long-term lasting effects. The FDA reviewed these records, and in collaboration with Cortexyme the decision was made to hold the OLE while continuing with GAIN. This decision allows the main thrust of the program to continue, while working out a new protocol for the OLE. The purpose of the OLE is to test long-term efficacy and tolerability of the drug. In a review of Cortexyme after the announcement, HC Wainwright’s 5-star analyst Andrew Fein noted, “Cortexyme's announcement of a partial clinical hold on the OLE study of atuzaginstat is disappointing, but the reversible nature of the liver toxicity might provide some ray of hope for Cortexyme. We believe that the pivotal trial's continuation suggests that the drug-induced liver injury might not be severe enough to halt the program.” Turning to the near-term, Fein adds, “Continuation of the GAIN trial is encouraging despite the partial hold on OLE. It suggests that FDA plans to wait for the additional data from the pivotal trial before coming to any conclusion. Management shared that nearly one-third of the GAIN patients have completed the study and way past the 12-week time point, suggesting that they are out of risk.” To this end, Fein rates CRTX a Buy, and his $76 price target indicates confidence in a 147% growth potential. (To watch Fein’s track record, click here) Overall, Cortexyme has a Moderate Buy rating from the analyst consensus, with 6 recent reviews breaking down 4 to 1 to 1, Buy-Hold-Sell. The stock’s $83.60 average price target suggests that Wall Street sees a high potential here, on the order of ~170% upside from the trading price of $30.74. (See CRTX stock analysis on TipRanks) Immunovant (IMVT) Next up is Immunovant, a clinical stage biopharmaceutical research firm, focused on developing treatments for patients with autoimmune disorders, a class of diseases in which the immune system attacks the patient’s own body. The firm’s lead drug candidate, IMVT-1401, is undergoing trials as a treatment for thyroid eye disease, myasthenia gravis, and warm autoimmune hemolytic anemia. The drug described as “a novel, fully human anti-FcRn monoclonal antibody,” delivered by subcutaneous injection. On February 2, Immunovant’s stock plunged 42%, and it has been falling ever since. The precipitating factor was an announcement by the company that IMVT-1401 has had its Phase 2b clinical trial, for thyroid eye disease, halted temporarily, due to patients experiencing dangerous rises in their LDL levels. LDLs are the potentially harmful form of cholesterol, which have been connected to cardiovascular disease. Despite the clinical setback, Stiffel’s 5-star analyst Derek Archila reiterated a Buy rating on IMVT shares, along with a $28 price target. This figure suggests a 52% upside potential from current levels. (To watch Archila’s track record, click here) “Interestingly, increases have only been seen in TED patients, and our review of the literature suggests a few things: (1) it's likely this is TED specific given the biology- see below for details, but we don't think similar LDL increases will be seen in other indications outside TED; and (2) other anti-thyroid therapies used in Graves/TED also see similar increases in LDL, which end up being transient. We think IMVT-1401, in away, is replicating this mechanism," the analyst noted. Archila summed up, "While we will need to see additional data from the company to confirm... we don't think this program is dead.” Overall, the Strong Buy analyst consensus view on IMVT would suggest that Wall Street generally agrees with Archila’s assessment. This rating is derived from 8 recent reviews, which include 7 Buys and only a single Hold. The average price target here stands at $40.38, implying ~121% upside for the next 12 months. (See IMVT stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Tilray Beats Some Earnings Views, Achieves This Rare Feat Among Marijuana Stocks

    Tilray beat some Q4 expectations, and became the rare weed company to deliver on its profitability goals.

  • What Rate of Return Should I Expect on My 401(k)?

    There's no one number. Pinpoint what you’ll need in retirement and your time frame until that day, and derive what to expect from your 401(k) from that.

  • Elon Musk Loses No. 1 Status As Tesla Stock Falls, But SpaceX Value Jumps

    Jeff Bezos is again the richest person in the world, reclaiming his title from Elon Musk, who has seen his wealth lag with the recent drop in Tesla stock.

  • Lithium producer Albemarle expects recovery in sales as results top estimates

    After the coronavirus dented growth prospects last year, Albemarle and its peers like SQM are now expecting to cash in on surging demand for the battery metal lithium, critical to electric vehicles that have become massively popular amid climate change concerns. Albemarle has earlier said it looks to double production at its lithium facility in Silver Peak, Nevada, part of a plan to boost supply for the burgeoning electric vehicle market, while Chilean miner SQM has said its current plans to boost its production of lithium carbonate and lithium hydroxide by the second half of 2021 remained on track. However, Albemarle warned that it expects pricing to be down slightly, and forecast adjusted profit in the range of $3.25 to $3.65 per share for 2021.

  • Big Freeze in Texas Is Becoming a Global Oil Market Crisis

    (Bloomberg) -- What began as a power issue for a handful of U.S. states is rippling into a shock for the world’s oil market.More than 4 million barrels a day of output -- almost 40% of the nation’s crude production -- is now offline, according to traders and executives. One of the world’s biggest oil refining centers has seen output drastically cut back. The waterways that help U.S. oil flow to the rest of the world have been disrupted for much of the week.“The market is underestimating the amount of oil production lost in Texas due to the bad weather,” said Ben Luckock, co-head of oil trading at commodity giant Trafigura Group.Brent crude surged to within 25 cents of $65 a barrel on Wednesday, a level not seen since last January. Ten months ago it slumped below $16 because of a demand shock caused by Covid-19. In the past the weather-related disruption would largely have been a U.S. issue. Now it’s unmistakably global. Crude markets in Europe are rallying as traders replace lost U.S. exports. OPEC and its allies must decide how much longer they keep millions of barrels of their supply off the market.Estimates for how long the outages may last have gotten progressively longer in recent days as analysts try to figure out the timespan involved in thawing out infrastructure, especially in those areas where freezing weather isn’t the norm.Higher EstimatesAt first, traders and consultants expected a hit to U.S. production that would last between two and three days. Now it’s looking unlikely that things will start to recover much before the weekend.That means ever more barrels are being removed from the global market. Citigroup Inc. said it expects a production loss of 16 million barrels through early March, but some trader estimates are now almost double that. Vast swaths of production in the Permian -- the heartland of U.S. shale output -- have been shut in.The result has been a surge in the value of crude barrels in other parts of the world. North Sea traders have been frantically bidding for the region’s cargoes this week as replacements are sought for U.S. crude exports. As Europe’s supplies have gotten more expensive, Asian buyers have been snapping up Middle Eastern shipments at higher premiums.And though headline crude futures are at their highest level in over a year, they’re yet to rip higher because the loss of refining capacity is equally acute. The country’s largest plant has closed, and at least 3 million barrels a day of processing got taken offline. Traders are rushing to send millions of barrels of diesel across the Atlantic to the U.S., a potential boon for Europe’s downtrodden refining industry.Gasoline Machine“The Gulf Coast is a gasoline machine and sends products across the U.S. as well as international markets,” said Kitt Haines, analyst at consultant Energy Aspects. “For a brief period at least, this could help European refining.”The result is going to mean a mixed picture for U.S. inventories in the coming weeks. While gasoline production has been hit by the spate of refinery outages, there are also far fewer drivers on the roads than normal. Stockpiles of heating fuels like propane and diesel -- for which demand was already soaring before this week’s weather -- are set to fall sharply.All of which leaves Saudi Arabia and its allies in the Organization of Petroleum Exporting Countries keenly watching the forecast for Texas’s weather.April DecisionThe group is yet to decide on its output plans for April, but OPEC’s largest producer surprised oil markets earlier in the year by cutting an extra million barrels a day of supply in February and March. That leaves spare capacity on the sidelines at a time when the market is clamoring for extra barrels.“The market is turning into a wild animal for OPEC+ to control,” said Gary Ross, a veteran oil consultant turned hedge fund manager at Black Gold Investors LLC. “The weather is having an unbelievable impact on global supply and demand.”A thaw is coming, though. On Friday, temperatures in Midland -- the de facto capital of shale production -- will reach 45 Fahrenheit (7 degrees Celsius). That will rise to 56 Fahrenheit on Saturday, allowing crude production to restart. On Monday, Midland hit -2 Fahrenheit, its lowest temperature in more than 30 years.For the time being, the great unknown remains how long output -- and the rest of the region’s oil infrastructure -- will take to recover in full.“Evidence from the last great Permian freeze off is that it can come back very quickly,” said Paul Horsnell, head of commodities research at Standard Chartered Plc. “But refineries are more likely to be prone to prolonged damage.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Apple stock breaks below post-COVID uptrend line after largest shareholders disclose share sales

    Shares of Apple Inc. sank toward a one-month low Wednesday, and broke below two key chart levels in the process, after the technology behemoth's two largest shareholders disclosed that they trimmed their stakes.

  • The IRS says it’s done sending stimulus checks for now — here’s how to get your money if you were eligible and missed out

    The IRS issued more than 307 million direct payments worth a combined $412 billion during the first and second round of stimulus checks.